Drugs / ZS801
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05641610 | Feb 2022 → Dec 2025 overdue | hemophilia B | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05630651 | Apr 2023 → Dec 2025 overdue | hemophilia B | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZS801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05630651 ↗ |
| Action | Restore | “designed to drive expression of the human factor IX (hFIX) transgene and raise circulating levels of endogenous FIX” NCT05641610 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant.” NCT05630651 ↗ |
| Route | Intravenous | “Single intravenous (i.v.) infusion of ZS801” NCT05630651 ↗ |